Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05856695
Title A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) (TAXIO)
Acronym TAXIO
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Intergroupe Francophone de Cancerologie Thoracique
Age Groups: senior | adult
Covered Countries FRA

No variant requirements are available.